(Press-News.org) Q: How would you summarize your study for a lay audience?
Cells contain helper molecules called transfer RNAs (tRNAs), which carry building blocks (amino acids) to make proteins. These tRNAs can be broken down into smaller pieces called tRNA-derived RNAs (tsRNAs or tDRs) that have new jobs - to help cells deal with stress and challenging situations.
In this study, we focused on one specific tDR, called tRNA-Asp-GTC-3’tDR, which becomes more abundant during stress. tRNA-Asp-GTC-3’tDR is present at baseline in kidney cells and increases in response to disease-related stress signals in cell culture and several mouse models of kidney diseases. Importantly, its levels are also higher in human conditions like preeclampsia and early kidney disease.
tRNA-Asp-GTC-3’tDR helps protect kidney cells by regulating a critical process called autophagy, where cells break down and reuse their own parts. Blocking tRNA-Asp-GTC-3’tDR in kidney disease models led to more kidney damage, including cell death, inflammation, and scarring.
To test if boosting this tDR could help, we developed a way to increase its levels in mouse kidneys. Mice had more kidney protection with less scarring, inflammation, and injury when this tDR was present at higher levels.
We also learned that the tDR’s unique folded shape, called a G-quadruplex, is essential for its protective effect. This shape helps it bind to proteins that manage autophagy, making it a potential new target for kidney disease treatments in the future.
Q: What question were you investigating?
We sought to determine the regulation and function of the novel tRNA-Asp-GTC-3'tDR that increases markedly with stress in different cell types and is expressed at high levels at baseline in metabolically active tissues and cells.
Q: What methods or approach did you use?
We developed new tools to assess its biogenesis, reagents to silence this molecule selectively using machine learning approaches and deliver/increase its levels. These tools allow precise control of its levels to investigate its role and therapeutic potential in cell culture and disease models.
Q: What did you find?
We found that the hypoxia-responsive tRNA-Asp-GTC-3’tDR maintains cellular homeostasis in kidney cells by regulating autophagic flux and plays a key role in the stress response. The levels of tRNA-Asp-GTC-3’tDR increased acutely in animal models and human cell cultures to enhance autophagic flux and protect against cellular injury, inflammation and fibrosis.
Q: What are the implications?
We identified a promising RNA molecule that could be therapeutically targeted to treat patients with kidney diseases, such as chronic kidney disease.
Q: What are the next steps?
We are developing platforms and tools to study the therapeutic potential of this tDR in kidney and heart disease. These new tools will help determine safety, durability and any toxicity of treatments. Additionally, we are developing Cas13-based RNA editing tools to enhance the expression of the endogenous tDR, a far more efficient way to manipulate the cell’s own tDR.
Authorship: In addition to Li and Das, Mass General Brigham authors include Lingfei Sun, Cuiyan Xin, Tian Hao, Prakash Kharel, Priyanka Gokulnath, Chunyang Xiao, Hanna Y. Wang, Emeli Chatterjee, Seungbin Yim, Leo B. Ren, Michail Spanos, Haobo Li, Oluwaseun Akeju, Pavel Ivanov and Joseph V. Bonventre.
Paper cited: Li, G., et al. “A hypoxia-responsive tRNA-derived small RNA confers renal protection via RNA autophagy.” Science. DOI: 10.1126/science.adp5384
Funding: This work was supported by grants from the American Heart Association (23CDA1045944, 20CDA35310184 and 24SCEFIA1253853), the National Institutes of Health (R21DK137432, R01DK072381, AG077040, UG3CA241687, R01GM126150, R01GM146997, NHLBI R35HL150807, NCATS UG3TR002878, NIDDK R21DK137432, R01DK39773, R01DK072381 and R00HD096125), the Preeclampsia Foundation Canada Vision Grant 2021 and the National Institutes of Health/National Cancer Institute (P30CA33572).
Disclosures: Ravi V. Shaw has equity ownership in Thryv Therapeutics. Shaw is a co-inventor on pending patents or disclosures on cardiometabolic disease and RNA biomarkers. Akeju is a consultant and holds equity in Reversal Therapeutics. Bonventre is an inventor on KIM-1 patents assigned to Mass General Brigham. Bonventre is a consultant to Sarepta, Mitsubishi-Tanabe, GentiBio and Praxis and has equity interests in Renalytix, DxNow, Oisin, VeriNano, Autonomous, Medical Devices, Pacific Biosciences, Medibeacon and Cascade Medical Systems. Das is a founding member and has equity and consulting agreements for Thryv Therapeutics and Switch Therapeutics, neither of which is relevant to this study. Li and Das. are co-inventors on a U.S. provisional patent application (WO2024264035A2) relating to tsRNA/tDR generation and engineering technology filed by Mass General Brigham.
END
Research spotlight: Study finds a protective kidney RNA that could transform disease treatment
2025-07-17
ELSE PRESS RELEASES FROM THIS DATE:
Research Spotlight: Study reveals an unexpected role for protein aggregates in brain disease
2025-07-17
Raghu R. Chivukula, MD, PhD, a physician-investigator in the Departments of Medicine & Surgery and the Center for Genomic Medicine at Massachusetts General Hospital and Harvard Medical School, is the senior author of a paper published in Science, “Polyglycine-mediated aggregation of FAM98B disrupts tRNA processing in GGC repeat disorders.”
Q: How would you summarize your study for a lay audience?
Neurodegenerative disorders, such as Alzheimer’s disease and Parkinson’s disease, are devastating and incurable diseases. Although many neurodegenerative ...
UK Government and UK Research and Innovation join forces to launch multi-billion-pound compute roadmap
2025-07-17
Quicker health diagnoses, smarter energy supplies, tackling climate change and improved public service delivery – just some huge potential benefits of the new compute roadmap, launched by DSIT and UKRI.
The roadmap heralds a significant increase in publicly accessible compute capacity. Investments include up to £2 billion to deliver a holistic and user-centred compute ecosystem with £1 billion to expand the AI Research Resource 20-fold by 2030.
It also provides up to £750 million for UKRI to invest in a new national supercomputing service at Edinburgh.
UKRI is further ...
New study in JAMA Network Open shows current approaches to assessing preeclampsia risk are failing the majority of pregnant moms
2025-07-17
South San Francisco, CA (July 17, 2025) - A new study sponsored by Mirvie, which is the first to evaluate U.S. Preventive Services Task Force (USPSTF) guidelines for preeclampsia risk and aspirin prescription in a single, nationally representative, prospective population, found while high-risk factors had sufficient value in estimating risk, there’s limited value for the moderate risk category - leading to nonspecific recommendations for aspirin use, a recognized prevention tool.
This cohort study of 5684 participants, culled from the multi-center Miracle of Life prospective study, found the guidelines ...
An FDA-backed metric used to determine effectiveness of rectal cancer drugs may be unreliable, says new study
2025-07-17
A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising concerns that some treatments may be fast-tracked for approval without evidence they help patients live longer.
The study, published in JAMA Network Open in collaboration with researchers at Mayo Clinic in Arizona, found that the absence of detectable tumors after treatment – a key metric in clinical cancer drug trials known as pathologic complete response or pCR – does not reliably predict an improvement in long-term survival for patients diagnosed with ...
Research Spotlight: evaluating the effectiveness of guidelines to predict the risk of preeclampsia
2025-07-17
Q: How would you summarize your study for a lay audience?
Dr. McElrath: Preeclampsia (PE) is a hypertensive disease that complicates 7-10% of pregnancies. While recent advances in understanding the underlying causes of PE have been made, predicting its occurrence has historically been difficult because it is a complex condition that likely results from a variety of causes and can present in different ways.
To address this challenge, the United States Preventive Services Task Force (USPSTF) reviewed ...
Pigment researchers create vivid yellows, oranges, reds that are durable, non-toxic
2025-07-17
CORVALLIS, Ore. – Oregon State University pigment researchers are using a rare mineral discovered in Norway more than a century ago as a road map for creating new yellows, oranges and reds that are vibrant, durable, non-toxic and inexpensive.
The new pigments also carry energy-saving potential: Their ability to reflect heat from the sun means that buildings and vehicles coated in them will require less air conditioning.
The study led by Mas Subramanian, who made color history in 2009 with the discovery of a vivid blue pigment now known commercially as YInMn Blue, was published in Chemistry of Materials.
Funded by the National Science Foundation, ...
Increased transparency about how countries use AI to manage migration needed, new study shows
2025-07-17
Increased transparency from countries about how they use AI to manage migration is needed to boost trust and strengthen the rule of law, a new study says.
Any overuse of AI in migration management may perpetuate biases and errors, promoting excessive reliance on technology and undermining trust in decision‑making processes, an expert has warned. Adequate cybersecurity measures are also needed to protect sensitive data about vulnerable migrants.
However, using AI for migrant management could present opportunities such as freeing up caseworkers’ time to focus on other critical areas, ...
Scientists repurpose old solar panels to convert CO2 exhaust into valuable chemicals
2025-07-17
Centuries ago, alchemists worked furiously to convert the common metal lead to valuable gold. Today, chemists are repurposing discarded solar panels to create valuable organic compounds from carbon dioxide (CO2), a common greenhouse gas.
Significantly reducing greenhouse gasses in the atmosphere to mitigate the most devastating effects of climate change will require a large reduction in emissions as well as strategies designed to sequester emitted CO2 and other offending gasses. While simply sequestering ...
Epidemiology: Key predictors of avian flu outbreaks in Europe identified
2025-07-17
Several local factors — including the minimum temperature reached in autumn, the water level in lakes and ponds in winter, and the presence of mute swans (Cygnus olor) — could be key for predicting the potential of an outbreak of highly pathogenic avian flu (HPAI) occurring in Europe. The findings, published in Scientific Reports, are derived from a machine learning model trained on the characteristics of 21st century European HPAI outbreaks and could help improve future monitoring programmes.
HPAI outbreaks are a serious concern for both animal and public health. A wave of HPAI outbreaks across the Northern Hemisphere during 2022 were associated with an ...
Global rise in many Early-Onset GI cancers detailed in two Dana-Farber reviews, with colorectal cancer leading the trend
2025-07-17
Boston, MA – July 17, 2025 – Early-onset gastrointestinal (GI) cancers are rising at alarming rates worldwide and, in the U.S., are increasing faster than any other type of early-onset cancer, including breast cancer, according to two recent literature reviews from Dana-Farber Cancer Institute.
"Early-Onset Gastrointestinal Cancers: A Review," published today in JAMA, provides a comprehensive analysis of the incidence, risk factors, and treatment approaches for early-onset GI cancers. Authors note the rising rate goes ...